Maat Pharma S.a. Stock
Price
Target price
€7.74
€7.74
-5.610%
-0.46
-5.610%
€10.00
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Maat Pharma S.a. Stock
Maat Pharma S.a. took a tumble today and lost -€0.460 (-5.610%).
The community is currently still undecided about Maat Pharma S.a. with 1 Buy predictions and 0 Sell predictions.
With a target price of 10 € there is a positive potential of 29.2% for Maat Pharma S.a. compared to the current price of 7.74 €.
So far the community has only identified positive things for Maat Pharma S.a. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Maat Pharma S.a. in the next few years
Pros
?
S********** s********
?
B****
?
C******** o* t** e**********
Cons
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
News
MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2024
Regulatory News:
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to
MaaT Pharma Presents Positive 18-month Data for MaaT013 Showing a Clear Overall Survival Advantage in aGvHD from the Early Access Program at the 2024 EBMT Event
Regulatory News:
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies™ (MET) dedicated to
MaaT Pharma Presents Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies
Regulatory News:
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to